Phenyl-imidazolyl-alkanyl derivatives, their production and use

ABSTRACT

Phenyl-imidazolylalkanyl derivatives are antimycotic agents. They are prepared by a number of processes including acylation or sulfonylation of a phenyl-imidazolylalkanol, treatment of a phenyl-alkanyl-carbinol with a diimidazolyl sulfone, oxidation of a phenyl-imidazolylalkylmercaptan or reduction of a phenylimidazolylalkanoate or alkanonitrile. A typical embodiment is 1(1,1-diphenyl-2-acetoxyethyl)imidazole.

United States Patent Metzger et al.

PHENYL-IMIDAZOLYL-ALKANYL DERIVATIVES, THEIR PRODUCTION AND USE Inventors: Carl Metzger; Werner Meiser; Karl Heinz Buchel; Manfred Plempel, all of Wuppertal-Elberfeld, Germany Assignee: Farbenfabriken Bayer AG, Germany Notice: The portion of the term of this patent subsequent to Mar. 12, 1991, has been disclaimed.

Filed: Apr. 2, 1973 Appl. No.: 346,939

Related U.S. Application Data Division of Ser. No. 172,201, Aug. 16, 1971, Pat. No. 3,796,704.

Foreign Application Priority Data Aug. 22, 1970 Germany 2041771 U.S. Cl. 260/309 Int. Cl C07d 49/36 Field of Search 260/309 *July 1, 1975 References Cited UNITED STATES PATENTS 3,682,951 8/1972 Kreid eL. 260/309 3,717,655 2/1973 Godefroi et a1 260/309 3,732,242 5/1973 Buchel et a1. 260/309 3,749,701 7/1973 Engelhar'd 260/309 3,755,349 8/1973 Timmler et al. 260/309 3,796,704 3/1974 Metzger et a1 260/309 OTHER PUBLICATIONS Conant et al., The Chemistry of Organic Compounds 4th Ed., page 335, N.Y., MacMillan, 1952, QD251.C67.

Primary Examiner-Natalie Trousof 17 Claims, No Drawings 1 PHENYL-IMIDAZOLYL-ALKANYL DERIVATIVES, THEIR PRODUCTION AND USE This is a division of application Ser, No. 172,201 filed Aug. 16, 1971 US. Pat. No. 3,796,704, issued Mar.'l2, 1974.

DETAILED DESCRIPTION The present invention relates to new phenylimidazolylalkanyl derivatives and their salts, to processes for their production, and to their pharmaceutical use, especially as antimycotics.

The present invention provides phenyl-imidazolylalkanyl derivatives of the general formula:

in which:

Y is an oxygen (O--), or sulphur (S);

R is an optionally substituted lower alkoxy, lower alkenyloxy, lower alkynyloxy, lower alkylmercapto, lower alkenylmercapto, lower alkynylmercapto, aryloxy, arylmercapto, amino, mono(lower alkyl, lower alkenyl-, or lower alkynyl-) amino, di(lower alkyl-, lower alkenyl-, or lower alkynyl- )amino, monoaryamino, diarylaminojarylsulfonamido, or -N(lower alkyl)-CO-NH-lower alkyl;

R is hydrogengalkyl, alkenyl or alkynyl or an optionally substituted aryl radical;

each of R and R independent of the other, is hydrogen or optionally substituted alkyl, alkenyl, alkynyl or aryl radical;

each of R, R and R, independent of the other is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, lower alkylthio radical, or an electronegative group;

X is an oxygen or sulphur atom or an SO, 80 l\lH-, or N-R group, R being hydrogen or lower alkyl, lower alkenyl or lower alkynyl;

m is an integer from 1 to 6; and

n is O or 1, and their salts.

The term alkyl when employed herein refers to a straight or branched chain monovalent hydrocarbon group of from 1 to 8 carbon atoms. Alkenyl" refers to a similar monovalent hydrocarbon group having from 2 to 8 carbon atoms and a nonterminal carbon-carbon ethylenic unsaturated bond. Alkynyl similarly refers to a monovalent hydrocarbon group of from 2 to 8 carbon atoms having a nonterminal carbon-carbon acetylenic unsaturated bond. When qualified by the term lower", these groups will have no more than 6 carbon atoms, i.e. from 1 to 6 carbon atoms in the case of lower alkyl and from 2 to 6 in the case of lower alkenyl and lower alkynyl. Derivative substituents such as alkoxy, lower alkyl, lower alkylthio and the like, insofar as the hydrocarbon portion is concerned, are similarly defined.

These new derivatives and their salts have good activity against human-, animaland plant-pathogenic fungi and yeasts as well as against bacteria and protozoa such as Trypanosomae and Trichomonadae.

R R and R are hydrogen or lower alkyl, the latter preferably containing 1 to 4 carbon atoms, especially methyl. Particular preference is given to R, R and R being hydrogen.

R", R and R are lower alkyl, preferably methyl; lower alkenyl; lower alkynyl; lower alkoxy; lower alkylthio; each of the foregoing preferably containing l to 4 carbon atoms; hydrogen; or an electro-negative substituent such as fluoro, chloro, bromo and iodo, preferably chloro and bromo; nitro, trihalomethyl, preferably trifluoromethyl; cyano; lower alkylsulfinyl and lower alkylsulfonyl, as well as the corresponding lower alkenyl sulfinyl and lower alkylsulfonyl groups. Hydrogen, chloro and bromo are particularly preferred.

R is alkyl of l to 8 carbon atoms, alkenyl or alkynyl of 2 to 8 carbon atoms preferably containing no more than 4 carbon atoms, or an aryl group containing 6 to lO carbon atoms. The aryl group may be unsubstituted or substituted by one or more, preferably no more than two groups, which may be identical or different. These substituents are of the same scope as those set forth above for R", R and R The preferred aryl group is phenyl, unsubstituted or substituted by chloro or bromo. Unsubstituted phenyl is particularly preferred.

R" and R are alkyl of l to 8 carbon atoms, alkenyl or alkynyl of 2 to 8 carbon atoms, or aryl of from 6 to 10 carbon atoms. The alkyl, alkenyl and alkynyl groups can contain one or more substituents, preferably no more than two, which may be identical or different. These substituents are of the same scope as set forth above for R, R and R R can be alkyl, alkenyl and alkynyl, preferably containing l to 6, especially 1 to 4, carbon atoms, which can be optionally substituted by one or more, preferably no more than two, of the substituents set forth above for R, R and R R can also be aryl, aralkyl, aralkenyl and aralkynyl, the aliphatic component of the latter three preferably containing no more than 4 carbon atoms, and the aryl component of aryl, aralkyl, aralkenyl and aralkynyl preferably containing 6 or 10 carbon atoms. These groups can be substituted by one or more groups, preferably no more than two, which may be identical or different. These groups are of the same scope as those set forth above for R, R and R The preferred aryl is 3 phenyl which can be substituted by chloro, bromo or fluoro.

R can also be a straight-chain or branched, saturated or unsaturated aliphatic acyl, generally containing l to 8, preferably 1 to 6, and especially 1 to 5, carbon set forth for R, R and R The preferred aromatic acyl is a phenylacyl radical, a phenylacylfradical substituted by one or more, preferably one to three of the substituents chloro, bromo, fluoro, methyl, methoxy and/or nitro, and naphthylacyl; v

R can also be an alkylsulfonyl, alkenylsulfonyl or alkynylsulfonyl, or an ether of the general formula R O R in which R and R are straightbranched, hydrocarboe groups of l to 8, preferably l-to 6 and preferably 1 to 6 and especially .-l to 4 carbon atoms, unsubstituted or substituted by e more than twosubstituents, which may be identical or different, of the scope set forth above for R". R" and R. i I R can also be an arylsulfonyl of from 6 to lOcarbon atomslin the aryl component unsubstituted or substituted by'one or more, preferably no morethan .two groups, which can be identical or different, ofthe, scope set forth above for R, R and R'". The preferred arylsulfonyl is phenylsulfonyl, especially unsubstituted phenylsulfonyl and phenylsulfonyl substituted by chlor o or bromo. i

R can be lower alkoxy, lower alkenyloxy, lower al-. kynyloxy, lower alkylthio, lower alkenylthio, lower alkynylthio, amino. mono-(lower alkyl, lower alkenyl orlower alkynyl)amino or di-(lower alkyl, lower dike nylor lower alkynyl)amino. R preferably contains no more'than 4 carbon atoms in each hydrocarbon component, especially methyl and ethyl in the case oflower alkyl and two carbon units for the other hydrocarbon; the hydrocarbon component can be straight-chain or branched and unsubstituted or substituted by one or more substituents of the same scope as set forth above for R",.R and R The lower alkyl of monoalkylamino in particular'can be further substituted by a lower alkanoyloxy, preferably one containing no more than 5 carbon atoms, especially acet oxy and propionyloxy.

R can also be aryloxy. arylthio, mono- ,or di-(aryl)- amino radicals. or arylsulfonamide, the aryl component containing 6 or 10, preferably 6 carbon 'atorns, in each aryl part and substituted by one or more, preferably no more than 2 substituents of the scope set forth above for R, R and R The preferred aryl is phenyl, either unsubstituted or substituted by one or two chloro, bromo. or methyl groups.

R can also be the --N(lower alkyl)CONl-llower alkyl group, the two alkyl groups may beidentiea] or different and preferably containing from 1 to 4 carbon atoms, especially methyl or ethyl.

R can be lower alkyl, lower alkenyl and lower alkynyl, preferably containing 1 to 4 carbon atoms, espe cially methyl or ethyl. e

The preferred salts of the imidazolyl derivatives of the invention are those that are pharmaceutically tolerated. 'Ihese'salt's are' those withphysiolog'ically compatible acids, such as hydrohalic acids; c.g.', hydrochloric acid or hydrobromic acid; phosphoric acid;:mono and bifunctional c'arboxylic acids; and hydroxycarboxylic acids, such as acetic acid, 'rnaleic acid, su'ccinic acid, fumaric acid, tartaric acid, citric acid, salicylic acid, sorbic acid, lactic acid, and, l,5-naphthalene-disulfonic acid.

' A first preferred subclass ofeompounds falling within 'theclass'defined byForrhula l arethose of formula:

X is oxygen; sulfur; imino; or sulfonyl; I R is hydrogen; lower alkyl; phenyl or phenyl substituted by up to three substituents selected from the group consisting of lower alkyl, lower alkoxy, chloro, bromo, fluoro or nitro; R is lower alkyl or phenyl; R 'is hydrogen; lower alkylo'r phenyl;

R is hydrogen or lower'alkyl; R is hydi'ogen, lower alkyl, lower alkoxy, chloro, fluoro, bromo or'nitro, and n is 0 or I. A second preferred subclass of compounds falling within the class defined by Formula 1 are those of the formula:

i i H i wherein X is oxygen or imino, I

R is lower alkanoyl, halo(lower alkanoyl), lower alkylsulfonyl, or a benzoyl, phenyl(low er alkanoyl), diphenylflower alkanoyl), phenyl(lower a lkenoyl), naphthoyl or phenylsulfonyi group unsubstituted or substituted by up to three substituents selected from the group consisting of lower alkyl, lower alkoxy, chloro, bromo, fluoro or nitro;

R is lower alkyl or phenyl;

R is hydrogen; lower alkyl or phenyl;

R is hydrogen or lower alkyl; i v I,

R is hydrogen, lower alkyl. lower alkoxy, chloro,

fluoro, bromo or nitro and 1 A third preferred subclass of compounds falling within the class defined by Formula 1 are those of the formula:

R is hydrogen or lower alkyl; g g

R is hydrogen, lower alkyl, lower alkyl carbamyl,

" carbotlower alkoxy)methyl ene, unsubstituted or substituted phenyl, or unsubstituted or substituted phenylsulfonyl, wherein the substituents on phenyl consisting of lower alkyl and chloro-,-i and n is or l.

The invention further provides four processes for the production of the new imidazolyl derivatives and their salts. These processes are designated below as Process 1 etc. Process 1 is applicable to those derivatives of Formula I and salts inwlgich n is l and X is oxygen (O) or imino"(.'Nl:l{-). In this process a compound of the general formula:

V a A i ;:4, in which R to R", R to R and m are as defined for sEormul g; and Z is hydroxy or amino; is reacted with 'I an z lcylating of sulfonylating agent, and if a salt is re quired, the product is converted to the desired salt. Process 2 comprises reacting analcohol of the general formula:

in which R 10 R; Xi in and 11 areas defihed for Formula l, with a compound of the general formula:

'o nverting the product to the said salt.

are one? or two members selected fromthegroup in which R to R are as defined for Formula I in an in ert, preferably polar, solveri tfand, if. a.,salt is desired.

Process 3 is applicable to derivatives and salts in which X stands for the group S O It comprises oxidizing' a compound of the geher'al'fo'rrnula:

in which to R niand n are as defined for Formula l in acid solution, ancilif. zisalt is d esired;.ct )nv.rt-ing the product to the said salt i 1 Process 4 is applicable to derivatives and salts in which n is l, X is oxygen Q+ or imino (-NH-), and R is hydrogen. ltcornprisesireacting a compound of the ge neral formula: i

in which R to R.-, Rito R and iii} are as defined above and A is carboflowerlalkoxy or cyano with (prefera- Bly) an approximately stoichiometric amount of a complex metal hydride such asllithium aluminum hydride or sodium borohydride, inan organic solvent such as an ether (e,g. diethyl ether or tetrahydrofuran) or an alcohol-(such as ethyl alcohol), if necessary decomposing by the addition of water the complex thus'forin'ed, and,

if a salt is desired, converting the product to the" 'said salt.

@C-CH OH o=c=N--c1 @C-CH Q-CO-NH-Q-Cl l l a E34 (9) (III) The course of the reaction according to Process 1 m When the amine (l) and acetic anhydride are used can be illustrated y the o ng quation I. utilizing as starting components, then the course of the reaction the carbinol shown below (8) and acetic anhydride 218 according to Process 1 can be illustrated by the followstarting compounds: in'g equation (IV):

' C CO\ n n Q 0 KHZ ca co c-cz-x -OH CH 00 I I 4 @l 2 3 [:3

N i 7 (a) W C-.CH O.C0.CH

3 l c-cF -Ma-co-c v on coon 2 E I I 5 E When the same carbinol (8) is used, but pivaloyl chloride is used as acylating agent in the presence of a Process 2 can b illustrated by the f ll wing equw pr'otonbacceptorl trighylam'in h Process 1 is tion, utilizing the carbinol l l and the compound l2 trated y the fo lowmg equation. 40 as starting compounds:

n y I I 1 I l- Q-T-Cd Od h Cu-T-cOCl QC-CH -S-Q-CI l I-SO-I w "3 L" (11) (i2 (triethylamine) When the carbinol (8) and an isocyanate is used, e.g. p-chlorophenyl-isocyanate (9), then the course of the u reaction according to Process 1 can be illustated as fol- Process 3 can be illustrated by the following equation lows: U V

R- Hal in which R is an optionally substituted aliphatic or aromatic acyl or sulfonyl groups as defined above, or

Y ll 12 where Y and R are as defined above.

The carboxylic acid and sulfonic acid anhydrides used are preferably those of the formula (14):

R13 O R13 in which R and R 'are identical or different and are optionally substituted aliphatic or aromatic acyl or sulfonyl groups, or the group where Y and R are as defined above.

The isocyanates used are preferably those of the general formula:

in which R is an optionally substituted alkyl, aryl or aralkyl group or a CH -COO(lower alkyl).

When an acid anhydride is employed, Process 1 can be carried out in the presence or the absence of an inert polar solvent.

When an acid chloride or isocyanate is employed, Process 1 is generally performed in an inert polar organic solvent, including ethers such as diethyl ether and tetrahydrofuran; aromatic solvents such as benzene and toluene; cycloaliphatic solvents such as eyclohexane; lower dialkyl ketones such as acetone; aliphatic esters such as ethyl acetate, or a tertiary amine such as pyridine. The process is performed at from about 20C, preferably from about 50C to about C.

Process 2 is performed in an inert organic solvent, preferably in approximately molar amounts.

Examples of suitable solvents include aromatic solvents such as benzene or toluene; lower dialkyl ethers such as diethyl ether; chlorinated hydrocarbons such as methylene chloride, chloroform or carbon tetrachloride; and lower alkyl nitriles such as acetonitrile. Acetonitrile is particularly preferred as solvent.

The reaction of Process 2 is carried out at temperatures of from about 0 to C, preferably from about 20C to about 80C.

In Process 3, the reaction componenets are preferably used in approximately molar amounts. The process is preferably conducted in an aqueous medium, examples of which include aqueoussulfuric acid containing, for example, 20% of sulfuric acid, and concentrated acetic acid. Suitable oxidizing agents include potassium permanganate, hydrogen peroxide and chromic acid. The oxidizing agents can be used in stoichiometric amounts or in excess. The reaction temperature is from about 0 to about 20C, preferably from about 5 to about 10C.

The salts can be prepared in known manner from the free derivatives of formula l obtainable by the processes described above. v

The starting compounds required for the production of the new compounds are either known or can be obtained by known processes.

Some of the new compounds according to the inven- (16) 55 tion are listed by way of example in Table 1.

Table 1 Compounds of the general formula:-

|CCH OR' (17) Compound No. R m .p.

l H 144C 2 hydrochloride of 1 192C Compounds of the general formula:-

Compound N0.

TTM T T T Q T T 34- 0 U 00 AU 00 7. 87 2. 2 l 5 7 2 1 I I. 1 mm m m H D u u 0 u c m. l, m c O 0 O w O n v C C .I C .P LO C C 0H 0 v 1. v CC v C U rim HHml l l l. CC C C .C 1 4.86 7 on 9 O 1 Table 1 -Con1inucd Compounds of the general formula:-

Compound No. R R" mp.

35 Q (45) H [30C 36 O (43) p-Cl 138C CH 37 L --ICH; (46) H 128C CH Compound No. Formu|a: m.p.

on. 38 -4-0 Q Q (47) [48C I l CH :3 N

Compounds of the general formula:-

IR! @c-ca-on (48) I LN Compound No. R mp 39 (H l54C Compounds of the general formula:-

(l-CH -CH -OR (49) Compound No. R m.p.

4] H 130C 42 CH:x-C 80C Compounds of the general formula:-

Compounds of the general formulac- Compound No. R R" m.p.

49 H CH (51) Compounds of the general formulaz- The production by the processes of the invention of certain derivatives and salts according to the invention is illustrated in the following Examples.

EXAMPLE 1 A solution of 26.6 g (0.0911 mol) diphenyl imidazolylacetic acid methyl ester in 300 ml of absolute tetrahydrofuran is added dropwise at room temperature (about C) to a suspension of 3.5 g (0.911 mol) LiAlH in 100 ml of absolute tetrahydrofuran. After stirring at C for 2 hours, the mixture is slowly heatedto C and the same temperature is subsequently maintained for 4 hours. The complex is decomposed at 10C with 10 g of 20% aqueous NaOH. The hydroxides are filtered off with suction and boiled several times with benzene. The benzene and tetrahydrofuran solutions are combined and concentrated by evaporation. The residue is compound No. 1 of the formula:

with a melting point of 144C (ethyl acetate); yield 16.5 g of theory).

C17H16N2O (264.3)

Cale: N 10.6%

Found: N 10.7%.

When 10 g,.o,;the .baseobtainedin this way are dissolved in niliethylacetat and ethereal hydrochloric acid is added with Coolingythen the hydrochloride (Compound No. 2) slowly crystallizes.

M.p. 192C; yield 10.8 g (96% of theory).

l n n z l (3 0 The diphenyl-imidazolyl-acetic acid methyl ester re qifired as starting material is obtained as follows:

13 g (0.05..mol-) 'diphenyl-chloroace'tic acid methyl ester (b.p. C/0.1 mm Hg, prepared from diphenyla-chloroacetic acid chlorideandf methar'iol according to Ber. 22, 1537) are heated with 10 g imidazole in 100 ml acetonitrile at boiling ternperature for 18 hours. After distilling off the solvent in a vacuum, 100 m1 of water are added, and the mixture is extracted with methylene chloride. After drying over sodium sulphate, the solvent is distilled off in a vacuum and the residue is recrystallized from a little ethyl acetate.The d iphenyl-imidazolyl-acetic acid methylesterof m.p.-'

C (decomposition) is thus obtained.

The other starting compounds of this type can be obtained in an analogous way.

The compounds Nos. 41. 43 and 45 listed in Table 1 can be obtained according to the process of Example 1 from the following starting materials:

Starting Material Product diphenyH imidazolyl-l )-acctic acid Compound 41 methyl-ester tcrt.but \'1-phcn)'1-(imidazolyll-)-acetic acid methylester isopropyl-phenyl-(imidazolyl-1 l-ac etic acid methylester Compound 43' v I Compound EXAMPLE 2 g 5 g (0.01895 mol) ;l,l-diphenyl-l-imidazolylethanol-2 are heated with ml acetic anhydride and 0.5 g of anhydrous sodium acetate at 100C for 2 hours. After cooling, the, mixture is poured into 200 m1 of water and stirred until the acetic anhydride odor disappears. The mixture is then clarified with animal charcoal, rendered alkaline, and extracted with ether. After evaporation of the ether, there remains compound No. 3 of the formula: I

with a inelting point of 83C; (ligroin/ethyl acetate); yield2.9"g'(50% of theory).

Calc.: C, 74.4%; H, 5.9%; N, 9.16%.

Found: C, 74.0%; H, 6.0%; N, 9.18%.

The compounds .Nos. 4, 6, 42, 44 and 46 listed in Table l can'be'obtained'according to the process of Example .2 from the following starting materials:

Starting Material Product ll-diphenyll -imidazolyl-ethanol-2. Compound 4 propionic-anhydride and sodium propionate l, l -diphenyll -imida2olyl-ethanol-2. Compound 6 dichloroacetic-acidmnhydride and sodium dichloracetate 1 ,1-dipheny1l imidazolyl-propanol-3. acetic-acid anhydride, butanol-4 and sodium acetate I 2,2-dimethyl-3-phenyl-3-imidazolyl. acetic. acid anhydride butanol-4 and sodium acetate K 2,'. Z;dimethyl-3-phenyl 3-imidazolylmono-4 .propionic anhydride andsod ium propio'rlate C ompound 42 Compound 44 Compound 46.

H EXAMPLE3 5.28 g 0 .02 mi 1,1 diphenyl- 1 -imidaz olylethanol- 2 are dissolvedin 16 ml pyridine. 3.5 g,4-chlorobenzoyl chloride (0.02 mol) are slowly added dropwise; the temperature must remain below 20C. After stirringovefr night, the mixture is poured into ml of ice water, the product is filtered off with suction and thoroughly washed with water. Compound No. 8 obtained in this way corresponds to the formula 1 Product Acid Chloride Benzoyl chloride Compound 7 2-Chlorobenzoyl chloride Compound 9 3.4-dichlorobenzoyl chloride Compound 10 I 3.6-dichlorohcnzoyl chloride Compound 1 1 2.3,4-trichlorobenzoyl chloride Compound 12 4-fluorobenzoyl chloride Compound 13 4-bromohenzoyl chloride 1 C ornpound 14 Compound 15.

4-nitrobenzoyl chloride Compound 16 3.5-dinitrobenzoyl chloride 3'nitro-4methoxybcnzoyl chloride v 1 ..Compound 17' I 4-methyihenzoyl chloride i; t h Compound 18, 4-methoxy benz'oyl chloride Compound 19 Cinnamoyl cliloridc' Compound 20 wnaphthoyl chloride i 1 I Compound 21 Compound 22 diphenylacetyl chloride I Compound 4 chlorophnylsulfonyl chloride. i x

' 'E'XAMPL'E'4 5.28 g (0.02 mol) l,l diphenyl-l imidazolyl-ethanolare dissolved in 16 ml py'ridine. 4 g methanesulfofchloride are added dropwise in such a manner that the temperature always remains be10w,20C. After stir- .ring over-night, the mixture is'poured into 160 ml of ice-water. The product is filtered off with suction and thoroughly washed. Compound No. 24-obtained in this way corresponds to the formula andhas a of 187C (ethanol); yield 5.7 g (83% of theory);

C l-1 01 0 5 c2110.: C, 63.1%; H, 5.26%; N, 8.18%. Found: C, 63.1%;1-1, 5.1%; N, 8.1%.

EXAMPLE 5 5.28 g (0.02 mol) 1,1-diphenyl-imidazolyl-ethanol-IZ are dissolved in l6'ml pyridine. 3 g dimethyl-carbamic acid chloride are added dropwise in such a manner that 1' CH -O-CO-il CH3 crystallizes out; m.p. 151C (ether); yield 6.35 g (85% of theory).

Calc.: N, 11.3%.

Found: N, 11.1%.

EXAMPLE 6 5.28 g (0.02 mol) 1,l-diphenyl-l-irnidazolyl-ethanol- 2 are dissolved in 40 ml ethylene chloride, and 3.3 g isocyanate-acetic acid ethyl ester and 3 drops of triethylamine are added. After standing for 3 days, the mixture is distilled in a vacuum, the residue is boiled with absolute ether, whereupon crystallization sets in. Compound No. 27 obtained in this way corresponds to the formula Q-Q L7;

and has a m.p. of 105C (ether); yield 5.7 g (73% of theory).

Calc.: C, 67.2%; H, 5.85%; N,.l0.7%.

Found: C, 66.3%; H, 6.0%; N, 10.7%.

The compounds Nos. 25, 28, 29 and 30 listed in Table 1 can be obtained according to the process of Example 6 from 1,l-diphenyl-l-imidazolyl-ethanol-l and the following reagents:

Reagent Product Compound 25 Compound 28 Compound 29 Compound 30 methylisocyanate 4-chlorophcnylisocyanate 3 ,4-di-chlorophenylisocyanate p-toluolsulfoisocyanate EXAMPLE 7 and a-chloroacetophenone) in 400 ml of absolute ether and 100 ml benzene are added dropwise to a Grignard solution of g magnesium and 38.8 g bromobenzene in 200 ml of absolute ether. When the exothermic reaction has subsided, the solution is decanted from the small residue and the ether is distilled off in a vacuum.

The residue is decomposed with ice-water and dilute sulfuric acid and extracted with methylene chloride.

After washing with water, the product is dried and the solvent distilled off in a vacuum. When the residue is digested with absolute ether, there is obtained some starting material of m.p. 80C, which is filtered off with suction. The filtrate is distilled off in a vacuum. The compound obtained in this way corresponds to the formula liH s c1 and has a m.p. of 55C (ligroin); yield 30 g (44% of theory).

C H ClOS (340.5):

Calc.: Cl, 10.42%.

Found: Cl, 11.15%.

The alcohols suitable for the preparation of the comf- (62 on pounds Nos. 31, 32, 35, 36, 37 and 38 listed in Table l as well as all other alcohols of this type which can be used according to the invention are obtainable in an analogous way.

Compound in Table l Melting point of alcohol suitable as starting compound No. (9

EXAMPLE 8 l 1.1 g (0.093 mol) SOCL are slowly added dropwisee at 0 to 5C to a solution of 27.8 g (0.409 mol) of purified imidazole in 500 ml of absolute acetonitrile. After stirring at 0C for minutes, the imidazole HCl is filtered off with suction. 29.2 g (0.086 mol) S- (pchlorophenyl)-l ,1-diphenyl-mercaptoethanol- 1(Example 7) dissolved in 100 ml of absolute acetonitrile are added to the filtrate, and the mixture is heated at to 40C for 4 hours, subsequently at C for 30 minutes, at C for 20 minutes, and under reflux for 1 hour. After evaporation of the solvent, 400 ml ether and 300 ml H O are added to the residue. The ether solution is separated, washed several times with water, dried, and ether HCl is added until the reaction is acidic. The precipitated hydrochloride is dissolved in H O, the solution is clarified with animal charcoal, rendered alkaline, and extracted with ether. After evaporation of the ether, there remains compound N0. 47 of the formula which has a melting point of 126C (ethyl acetate); yield 9.5 g (27% of theory).

CggHmClNgS Calc.: C, 70.6%, H, 4.86%; Cl, 9.09%; N, 7.16%; S, 8.19%.

Found: C, 70.2%; H, 4.76%; Cl, 9.02%; N. 7.17%; S, 8.24%.

The compounds Nos. 31, 32, 35, 36, 37 and 38 listed in Table 1 can be obtained according to the process of Example 8 from dimidazolyl sulfone and the following alcohols:

Alcohol Product Compound 31 Compound 32 Compound 35 Compound 36 o-phenyl-l 1 -diphenyl-glycol O-(p-ch1orophenyl)-l .l-diphenyl-glycol O-( 2-chlorophenyl l l -diphenyl-glyco1 O-phenyll-phenyll 4-chlorophenyl glycol O-terL-butyl-1,1-diphenyl-glycol O-(p-chlorophenyl)-2.2-dimethyl-l ,1- diphenyl-glycol Compound 37 Compound 38 EXAMPLE 9 of the formula:

I I Y. C C305 which has a melting point of 134C (ethyl acetate); yield 0.7 g (8% of theory).

:Calc; Cl, 7.39%; N, 5.82%.

Found: Cl, 7.75%; N, 5.79%.

EXAMPLE 12.05 g (0.1 mol) pivaloyl chloride are added dropwise at to C to a solution of 20 g (0.076 mol) l,l-diphenyl-l-imidazolyl-ethanol-Z and 0.1 g (0.1 mol) triethylamine in 700 ml of absolute acetonitrile.

The mixture is subsequently stirred at room temperature (about 20C) for 1 hour and then strongly cooled, The crystallized triethylamine hydrochloride is filtered off with suction and the filtrate evaporated. The residue is taken up in 200 ml methylene chloride, washedand has a m.p. of l 17C; yield 52% of theory.

EXAMPLE 11 25.9 g (0.1 mol) diphenyl-imidazolyl-acetonitrile in 200 ml of absolute ether are slowly addeddropwise at room temperature (about 20C) to a suspension of 2.7 g (0.07 mol) LiAlH in 100 ml of absolute ether. The mixture is subsequently stirred at room temperature (about 20C) for 2 hours and then heated under reflux for 4 hours. The complex is decomposed at 10C by the addition of 8 g of aqueous NaOH. The metal hydroxides are filtered off with suction and boiled several times with benzene. The ether solution and the benzene extracts are combined and completely concentrated by N-(2,2-diphenyl -2-imidazolyl)- evaporation. The ethylamine remains as an oil which crystallizes with absolute ether. l

To prepare the compound mentioned above, the amine is mixed with twice its weight of acetic anhydride and, when the reaction has'subsided, heated on a boiling water bathfor 30 minutes. By pouring ice-water into the mixture, compound No. 5-2 of the formula to Ber. 22, 1539) are heated with 200 g phosphorus oxychlorideat 110C for 3 hours. The phosphorus oxy- 5 chloride is distilled off in a vacuum. The residue is digested several times with methylene chloride, the methylene chloride is shaken with ice-water, dried and distilled. g diphenyl-a-chloroacetonitrile of b.p.

100C are obtained in this way.

The other starting compounds of this type which can be used according to the invention are obtainable in an analogous way.

EXAMPLE 12 13.3 g (0.05 mol) 1,l-diphenyl-1-(imidazo1yl)- propanone-2 are suspended in 50 ml ethanol, and 1.0 g sodium boron hydride (about 0.03 mol) are added at 0 to 5C. The mixture is stirred for 2 hours while cooling with ice, and allowed to stand overnight. 100 ml of water are then added, the pH is adjusted to 6-7 with acetic acid, the product is filtered off with suction, washed with water and dried.

ln this way there are obtained 12.3 g of compound No. 39 of the formula fgC-ii-DH @fi 64) in the form of colorless crystals; m.p. 154C; yield 12.3 g (96% of theory).

EXAMPLE 13 17.4 g 0.05 mol) diphenyl-benzoyl-(imidazol-1-yl)- methane are dissolved in 100 m1 tetrahydrofuran and 50 m1 ethanol, and 1.0 g sodium boron hydride is added at 0 to 5C. The product begins to crystallize after 1 to 2 hours, the mixture is diluted with ice-water, and the crystals are filtered off with suction. The compound No. 40 obtained in this way corresponds to the formula (iii-OH @f@ (65) and has a m.p. of 203C (dimethyl formamide/water); yield 16.3 g (93% of theory).

As has already been mentioned, the compounds according to the invention and their salts have an excellent antimycotic activity. This can be seen from the following tests carried out in vivo and in vitro:

Microbiological activity of the preparations 1. In vitro effect and type of activity against various humanand animal-pathogenic fungi.

The above preparations exhibit in vitro a good and wide ranging activity against humanand animalpathogenic fungi. The minimal inhibition concentrations (MIC) of some preparations against several species of fungi are indicated in Table 2 by way of example.

The nutrient media for the tests in vitro were:

a. for dermatophytes and mould fungi: Sabourauds milieu denreuve;

b. for gemmiparous fungi and biphasic fungi; meat broth/glucose broth The incubation temperature was 28C, the incubation period 48-96 hours.

Table 2 Determination of MIC against various species of fungi in the.

serial dilution test and agar diffusion test.

MlC in /ml Substrate The effect of the preparations is primarily fungistatic; fungicidal effects can be achieved in vitro with about three times the minimal inhibition concentrations.

A striking feature is the broad antimycotic effect of the aforesaid preparations, which extends to dermatophytes and mould fungi as well as to gemmiparous fungi, e.g. yeasts of the species Candida.

2. Antimycotic effect of the preparations in vivo:

a. Experimental candidosis. 1 Male mice (strain CF -SPF) of 20-22 g weight are intravenously infected with 1 X 10 cells of a Candida albicans culture. Untreated mice die, on average, after 4-6 days post infectionem from the organocandidosis developing after the infection. When the above preparations, especially the compounds Nos. 4, 5, 6, 8, 9, 16, 40, 47 listed in Table 1 are administered to Candidainfected mice per os with a throat probe twice daily in doses of 50-100 mg per kg body weight, starting on the day of infection, then of the animals survive the 6th day post infectionem, whereas only 5-10% of the untreated control animals survive the same period of time.

b. Experimental trichophytia of the mouse caused by Tric'lzophymn quinckeanum.

Male mice (strain CF,-SPF) of 20-22 g weight are infected on their shaven backs with spore suspension of Triclzoplzyton quinckeanum. A typical dermatomycosis withmultiple scutula formation develops at the point of infection within 12 days post infectionem.

When infected mice are treated, starting on the day of infection, per os with a throat probe with the preparations mentioned for the test 2(a) in doses of 2 X 75 2 X mg/kg daily for 8 days, the catching on of the infection and the typical scutula formation can be completely suppressed. 1

Among the untreated control animals 18 out of 20 animals exhibit scutula formation on the 12th day post infectionem, whereas among the treated animals I out of 20 animals exhibits scutula formation on the 12th day of post infectionem.

0. Experimental trichophytia of guinea pigs caused by Trichopliyton menlagrophytes.

Male guinea pigs of the strain Pearl-brightwhite, weight 400-600 g, are infected on their shaven backs with a spore suspension of Tric/wp/zyton mentagrophytes. The typical dermatomycosis with loss of hair and inflammatory changes of the skin develops at the point of infection within 14 days post infectionen.

When the infected animals are treated, starting on the 4th day post infectionem, with the preparations mentioned for the test 2(a), as a 1% solution in polyethylene glycol 400, locally once daily by brushing the solutions on to the point of infection, then the dermatomycosis is completely cured by the 1 2th day post infectionem, whereas it persists with the untreated animals until the 33rd-36th day post infectionem,

The aforesaid preparations have a mean DL for two animal species of 700-1 100 mg/kg body weight, when administered per os.

The imidazole derivatives and salts of the invention are to be applied in the therapy of dermatomycoses and organomycoses caused by Dermatophytes, mould fungi and gemmiparous fungi, especially species of Trichophyton, Microsporon and Epidermatophyton, Aspergillae, Penicillia and species of Mucor, species of Candida, Histoplasma, Coccidioides, species of Blastomyces, Cryptococcae and Chromomycetes:

Accordingly, the present invention provides a pharmaceutical composition containing as an active ingredient at least one of the new phenyl-imidazolyl-alkanyl derivatives of the general formula (1) given above, or a non-toxic salt thereof, in admixture with a pharmaceutically acceptable solid or liquid diluent or carrier as hereinafter defined.

In the present specification, the expression pharmaceutically acceptable diluent or carrier refers to a non-toxic solid, semi-solid, or liquid substance which when mixed with the active ingredient or ingredients renders it pure suitable for administration. Other pharmaceutically necessary ingredients such as salts in correct quantities to render the composition isotonic, buffers, surfactants, coloring and flavoring agents, and preservatives can also be present. Examples of suitable solid, semi-solid and liquid diluents and carriers include water; nontoxic organic solvents, such as paraffins (e.g. petroleum fractions) vegetable oils (e.g. peanut oil and sesame oil), alcohols (e.g. ethyl alcohol, glycerol), glycols (e.g. propylene glycol, polyethylene glycol); solid carriers such as natural stone meals (e.g. kaolins, aluminas, talc, chalk), synthetic stone meals (e.g. highly disperse silicic acid, silicates), sugars (e.g. raw sugar, lactose and glucose), cellulose and its derivatives. To these may be added emulsifiers such as nonionic and anionic emulsifiers (e.g. polyoxyethylenefatty acid esters, polyoxyethylene fatty alcohol ethers, alkyl-sulfonates and arylsulfonates); dispersing agents (e.g. lignin, sulfite waste liquors, methyl cellulose, starch and polyvinyl-pyrrolidone); and lubricants (e.g. magnesium stearate, talc, stearic acid and sodium lauryl sulfate). i

Examples of pharmaceutical compositions according to the invention are ointments, granules, pastes,

30 creams, sprays, lotions, aqueous and non-aqueous suspensions and emulsions, elixirs, syrups, and powders, either free-flowing or compressed into tablets.

The compounds and pharmaceutically acceptable salts of the present invention are preferably administered perorally, but may also be administered parenterally or locally. The compositions administered may contain other active ingredients.

One group of pharmaceutical compositions of the invention are therefore those adapted for oral administration. Examples of diluents and carriers that adapt the active ingredient or ingredients for oral administration are solid vehicles, excipients and lubricants such as glucose, lactose and sucrose, corn and potato starch, sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate. powdered gum tragacanth, gelatin, alginic acid, agar, stearic acid, sodium, calcium and magnesium stearates, sodium lauryl sulfate, polyvinyl pyrollidone, sodium citrate, calcium carbonate, and dicalcium phosphate, and talc.

The orally administrable pharmaceutical compositions of the invention may also contain other non-toxic adjuvants and modifiers such as dyes, surfactants, perfumes, flavoring agents, preservatives and biocides.

As stated above, the compounds and pharmaceutically acceptable salts of the invention may also be administered parenterally. Examples of diluents and carriers that adapt the active ingredient for parenteral administration are solvents and suspending diluents such as water and watermiscible organic solvents, in particular sesame oil, groundnut oil, aqueous propylene glycol, and dimethylformamide. Examples of pharmaceutical compositions of the invention are sterile isotonic saline aqueous solutions of the active ingredient, which may be buffered with a pharmaceutically acceptable buffer and are preferably pyrogen-free.

Local application can be carried out using a pharmaceutical composition adapted for such application. Such a pharmaceutical composition can contain, for example, 1% of the active ingredient, in a solvent such as polyethylene glycol 400 The pharmaceutical compositions of the invention preferably contain 0.5 to wt.% of a new phenyl imidazolyl-alkenyl derivative of the invention or a nontoxic salt thereof.

ln general it has proved expedient to administer amounts of 15 to 75, preferably about 50 mg/kg body weight, distributed over several applications (e.g. in 3 individual doses), per day, in order to achieve effective results. Nevertheless it may sometimes be necessary to deviate from the above amounts, dependent on the body weight of the subject being treated, the method of application, the species, individual reaction observed and desired, the type of formulation, or the time interval of administration. For example, it is sufficient in some cases to use less than the minimum amount mentioned above, whereas in other cases the aforesaid upper limit should be exceeded. The same range of dos age is envisaged for application in human and veterinary medicine.

The present invention also provides medicaments in dosage unit form as hereinafter defined comprising as an active ingredient at least one phenyl-imidazolylalkanyl derivative of general formula (1) given above or a non-toxic salt thereof, either alone or in admixture with a pharmaceutically acceptable solid or liquid diluent or carrier.

The expression medicament in dosage unit form" as used in the present specification means a medicament in the form of discrete portions each containing a unit dose or a multiple or submultiple of a unit dose of the active ingredient as for example, one, two. three or four unit doses, or a half, a third or a quarter of a unit dose. A unit dose is the amount of the active ingredient administered on one occasion and will usually be a daily dose, or a fraction thereof as for example a half, a third, or a quarter of a daily dose depending on the number of times the medicament is administered according to the daily regimen.

The discrete portions constituting the medicament in dosage unit form can include a protective envelope. The active ingredient can be in undiluted form in such an envelope, or can be mixed with a pharmaceutically acceptable solid or liquid diluent or carrier as defined above. Such portions can for example be in monolithic coherent form, such as tablets, lozenges, pills, suppositories, or dragees; in wrapped or concealed form, the active ingredients being within a protective envelope, such as wrapped powders, cachets, sachets, capsules. or ampoules; or in the form ofa sterile solution suitable for parenteral injection, such as ampoules of buffered, isotonic, sterile, pyrogen-free aqueous solution; or in any other form known in the art.

As stated above, it is preferred to administer the new phenyl-imidaZolyl-alkanyl derivatives of general formula (1) and their salts perorally. Preferred medicaments in dosage unit form according to the invention are therefore those adapted for oral administration, such as tablets, pills, dragees, capsules, and cachets, as well wrapped powders containing the active ingredient in powdered form with'a powdered diluent or carrier for suspension in water before being'taken.

As also stated above it is also possible to administer the new phenyl-imidazolyLalkenyl derivatives parenterally. Other medicaments in dosageunit form according tothe invention are therefore those adapted for parenteral injection, such as ampoules containing a measured quantity of a sterile isotonic saline injectable aqueous solution of the new active ingredient, which may be buffered with a pharmaceutically acceptable buffer and are preferably free of pyrogens.

The preferred unit dose for administration of the medicaments of the invention to a patient of average body weight is from about 4 to about 32 mg/kg of body weight, preferably about 16 to 20 mg/kg. This will normally be administered three times daily but may be adceutical composition according to the invention or a N l l E -02 -'x R 8 '5 7 2 R R R or a pharmaceutically acceptable non-toxic salt thereof, wherein X is oxygen or sulfur, or when R is other than hydro gen, sulfonyl;

R is hydrogen, lower alkyl, phenyl or phenyl substituted by l to 3 substituents selected from the group consisting of lower alkyl, lower alkoxy, chlorine, bromine. fluorine or nitro;

R is lower alkyl or phenyl;

R is hydrogen, lower alkyl or phenyl;

R is hydrogen or lower alkyl;

R is hydrogen, lower alkyl, lower alkoxy, chlorine,

fluorine, bromine or nitro; and

n is O or 1.

2. A pharmaceutically acceptable non-toxic salt of a compound according to claim 1.

3. A compound according to claim 1 wherein X is sulfur and R is hydrogen.

4. The compound according to claim 1 which is 1,1-

diphenyl-l-(imidazol-1-yl)ethanol-2.

5. The compound according to claim 1 which is 1,1

2-triphenyl-1-(imidazoll -yl)ethanol-2.

6. The compound according to claim 1 which is 1,1

diphenyl-l-(imidazol-l-yl)propanol-3.

'7. The compound according to claim 1 which is 1, 1-

diphenyl-1-(imidazol-1-yl)propanol-2.

8. The compound according to claim 1 which is 2,2-

dimethyl-3-phenyl-3-(imidazol-l-yl)butanol-4.

9. The compound according to claim 1 which is 2- methyl-3-phenyl-3-(imidazol-l-yl)butanol-4.

10. The compound according to claim 1 which is 2- methyl-3-phenyl3-(imidazol-l-yl)pentanol-5.

11. The compound according to claim 1 which is 1- l ,1-diphenyl-Z-phenoxyethyl )imidazole.

12. The compound according to claim 1 which is l- 1 .1-diphenyl-2-(4-chlorophenoxy)ethyl]imidazole.

13. The compound according to claim 1 which is 1- l, l-diphenyl-2-( 2-chlorophenoxy )ethyl]imidazole.

14. The compound according to claim 1 which is ll ,1-diphenyl'2-t-butoxyethyl)imidazole.

15. The compound according to claim 1 which is l- 1.1-diphenyl-2-methyl-2-(4-chlorophenoxy)propy1- limidazole.

16. The compound according to claim 1 which is ll1.1-diphenyl 2(4-chlorophenylthio)ethyl]imidazole.

l7. The compound according to claim 1 which is l- 

1. A COMPOUND OF THE FORMULA:
 2. A pharmaceutically acceptable non-toxic salt of a compound according to claim
 1. 3. A compound according to claim 1 wherein X is sulfur and R4 is hydrogen.
 4. The compound according to claim 1 which is 1,1-diphenyl-1-(imidazol-1-yl)ethanol-2.
 5. The compound according to claim 1 which is 1,1,2-triphenyl-1-(iMidazol-1-yl)ethanol-2.
 6. The compound according to claim 1 which is 1,1-diphenyl-1-(imidazol-1-yl)propanol-3.
 7. The compound according to claim 1 which is 1,1-diphenyl-1-(imidazol-1-yl)propanol-2.
 8. The compound according to claim 1 which is 2,2-dimethyl-3-phenyl-3-(imidazol-1-yl)butanol-4.
 9. The compound according to claim 1 which is 2-methyl-3-phenyl-3-(imidazol-1-yl)butanol-4.
 10. The compound according to claim 1 which is 2-methyl-3-phenyl-3-(imidazol-1-yl)pentanol-5.
 11. The compound according to claim 1 which is 1-(1,1-diphenyl-2-phenoxyethyl)imidazole.
 12. The compound according to claim 1 which is 1-(1,1-diphenyl-2-(4-chlorophenoxy)ethyl)imidazole.
 13. The compound according to claim 1 which is 1-(1,1-diphenyl-2-(2-chlorophenoxy)ethyl)imidazole.
 14. The compound according to claim 1 which is 1-(1,1-diphenyl-2-t-butoxyethyl)imidazole.
 15. The compound according to claim 1 which is 1-(1,1-diphenyl-2-methyl-2-(4-chlorophenoxy)propyl)imidazole.
 16. The compound according to claim 1 which is 1-(1,1-diphenyl-2-(4-chlorophenylthio)ethyl)imidazole.
 17. The compound according to claim 1 which is 1-(1,1-diphenyl-2-(4-chlorophenylsulfonyl)ethyl)imidazole. 